Cytokines represent a critical component in cell therapy manufacturing, supporting the expansion and maintenance of living cells. TheraPEAK® AmpliCell® Cytokines enable the reliable expansion, activation, and differentiation of immune cells. Produced in a mammalian expression system and engineered for high biological activity, these cytokines feature proper folding and glycosylation, delivering native-like structure and function that bacterial systems cannot match. This ensures superior biological relevance, batch-to-batch consistency, and greater predictability in sensitive and translational applications, both in research and GMP set-ups.

TheraPEAK® 293-GT® Medium is a chemically defined, animal–origin–free system optimized for adeno-associated virus (AAV) production in suspension HEK293 cells, providing a reliable, scalable option for advancing gene therapy programs. Unlike off-the-shelf viral production kits that may lack flexibility, the 293-GT® System (growth medium plus supplement) is a drop-in-ready solution engineered to integrate seamlessly with existing workflows. The media is compatible with commercially available transfection reagents and AAV enhancers, delivers strong AAV titers, and supports high full-to-empty capsid ratios.

TheraPEAK® Products have been used in FDA-approved therapies and more than 130 clinical trials across the globe. The newly-added solutions provide researchers and manufacturers with high-performance, scalable, and regulatory-ready solutions that streamline cell and gene therapy workflows from discovery through clinical development.

Mike Goetter, Head of Bioscience, Specialized Modalities, Lonza, said: "The introduction of AmpliCell® Cytokines and the 293-GT® Medium to our TheraPEAK® Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts."